

Appendix 1. Annotated Bibliography on Polypharmacy

Rena Kurs

Abstract Treatment resistance in schizophrenia and other mental disorders often challenges guideline-recommended monotherapy. Antipsychotic polypharmacy is thus increasingly encountered in clinical practice, and surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined psychotropic medications, usually for people with established psychotic disorders. To date there are no clear cut acknowledged evidenced based clinical practice guidelines for the use of psychotropic polypharmacy. The following annotated bibliography is a collection of representative publications on this controversial subject. The articles presented were chosen based on timeliness, and generalizability. They will be of interest to clinicians, multidisciplinary caregivers, and families of patients treated with psychotropic medications. There are links to the full text of open access publications, and to abstracts of articles available for purchase or to subscribers of the specific journals. For convenience sake, the publications have been divided into the following sections: General polypharmacy reviews and guidelines, Pediatric polypharmacy, and Disease specific polypharmacy. The last section includes links to various clinical practice guidelines for psychiatric disorders.

Publications appear in descending order of year of publication

Keywords Polypharmacy • Annotated bibliography • Clinical practice guidelines • Open access publications

R. Kurs, B.A. (✉)

Medical Library, Sha'ar Menashe Mental Health Center, Hadera, Israel
e-mail: rena@sm.health.gov.il

General Polypharmacy Reviews and Guidelines

Antipsychotic Polypharmacy: Update and Guidelines for Practice

Rajiv Tandon

An evaluation of the appropriateness of the many rationales for antipsychotic combinations with a brief outline of recommendations for the role of polypharmacy in antipsychotic therapy.

<http://medicaidmentalhealth.org/files/Guidelines/Antipsychotic%20Polypharmacy%20Update%20and%20Guidelines%20for%20Practice2012011708263376.pdf> (Full text).

Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. *Archives of General Psychiatry*. 2012 May;69(5):476–83.

The authors investigated whether the use of benzodiazepines, antidepressants, or multiple concomitant antipsychotics is associated with increased mortality among patients with schizophrenia

<http://www.ncbi.nlm.nih.gov/pubmed/22566579> (Abstract)

Antipsychotic polypharmacy: review of mechanisms, mortality and management

Julie LanganPolash Shajahan *The Psychiatrist* (2010) 34: 58–62

In this review the authors consider the reasons behind antipsychotic polypharmacy and the patterns of its use. They consider the evidence of effectiveness of combined therapy v. monotherapy and the rationale behind the potentially beneficial combinations that are used. The potential dangers of antipsychotic polypharmacy are also discussed and the limited research regarding switching from polypharmacy to monotherapy is reviewed. Some provisional recommendations regarding antipsychotic polypharmacy are proposed. <http://pb.rcpsych.org/content/34/2/58.full> (Full text).

Polypharmacy or medication washout: an old tool revisited

Hoffman DA, Schiller M, Greenblatt JM Iosifescu D

The authors discuss the role of washout, and whether it can help physicians select appropriate polypharmacy more effectively and safely, if necessary.

Neuropsychiatric Disease and Treatment 2011;7 639–648

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215520/pdf/ndt-7-639.pdf> (Full text)

Psychiatric Polypharmacy: Identifying Risks and Seeking Solutions

The Joint Commission Perspectives on Patient Safety, November 2008, Volume 8, Issue 11

Copyright 2008 Joint Commission on Accreditation of Healthcare Organization

Discusses four types of polypharmacy: same-class polypharmacy, multiclass polypharmacy, adjunctive polypharmacy, augmentation.

<http://ebookbrowse.com/polypharmacy-pdf-d98995356> (Full text)

Quality Concerns in Psychotropic Prescribing: Reducing Psychotropic Polypharmacy

Reference Guide

New York State Office of Mental Health

In 2007, the NYS Office of Mental Health convened a Scientific Advisory Committee of national experts in psychopharmacology. Six workgroups (schizophrenia, depression, bipolar disorder, older adults, youth, and women) identified approximately 80 quality concerns in psychotropic prescribing that are common, costly, and measurable. This clinical module provides information on the quality domain of polypharmacy, including an overview of the evidence base and definitions of each indicator.

http://www.omh.ny.gov/omhweb/psyckes_medicaid/quality_concerns/reference_guide/polypharmacy.pdf (Full text)

A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation

S.M. Stahl, M.M. Grady *Current Medicinal Chemistry*, 2004;11:313–327

This article reviews evidence for the increasingly common means of treating schizophrenia and psychosis, with particular emphasis on polypharmacy and augmentation.

http://www.nascos.org/library_files/Atypicals%20Review.pdf (Full text).

Polypharmacy in Psychiatry

S. Nassir Ghaemi *New York, NY: Dekker; 2002, 346 pages.*

This practical reference book examines the advantages and disadvantages of polypharmacy in psychiatry, and provides up-to-date clinical guidelines on the appropriate use of combinations of pharmacological therapy in major psychiatric disorders-including multidisciplinary approaches to treatment. The book consolidates available and current material on polypharmacy and psychiatry into one comprehensive volume. Polypharmacy in Psychiatry also discusses the use of alternative and herbal medications psychosocial aspects of polypharmacy the psychology of polypharmacy cultural components of polypharmacy historical background

http://books.google.co.il/books?id=TthcnM15c0sC&printsec=frontcover&hl=iw&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false (Excerpts from google books)

Decision Making in Psychopharmacology: Pocketbook

Siegfried Kasper, Joseph Zohar, Dan J. Stein

Martin Dunitz, Oct 10, 2002–112 pages

Rather than providing treatment guidelines this book highlights the different available avenues of treatment for mental disorders. Decision Making in Psychopharmacology is intended to stimulate discussion and clear thinking about the evaluative process.

http://books.google.co.il/books/about/Decision_Making_in_Psychopharmacology_Po.html?id=cvq5lNZCI_QC&redir_esc=y

NASMHPD Medical Directors' Technical Report on Psychiatric Polypharmacy

Approved by the NASMHPD Medical Directors Council October 9, 2001, for distribution to the NASMHPD Membership

This report is the seventh in a continuing series of reports initiated by the Medical Directors Council of the National Association of State Mental Health Program Directors (NASMHPD) (Alexandria, Virginia, USA).

The purpose of this report is to review information on the use of polypharmacy, to outline guidelines for the use of polypharmacy, and to make recommendations that decrease the inappropriate use of multiple psychiatric medications in patients with psychiatric illness.

<http://www.nasmhpd.org/docs/publications/archiveDocs/2001/Polypharmacy.PDF> (Full text).

Polypharmacy: When is it rational?

Sheldon H. Preskorn *Journal of Practical Psychiatry and Behavioral Health*, July 1995, 92–98

Though published in 1995, this is a landmark paper in which the author discusses when it makes sense to consider using more than one medication to treat a single condition. He gives a brief history of the use of polypharmacy in psychiatry and discusses how new discoveries in psychotropic drug development are making polypharmacy an increasingly important topic. The author then presents a list of ten criteria to guide the rational use of psychotropic polypharmacy and explains each in detail with examples drawn from clinical practice.

<http://www.preskorn.com/columns/9507.html> (Full text).

Pediatric Polypharmacy

The definition and prevalence of pediatric psychotropic polypharmacy

Chen H, Patel A, Sherer J, Aparasu R

Psychiatric Services. 2011 Dec;62(12):1450–5.

Using increasingly stringent criteria, this study evaluated the prevalence of psychotropic polypharmacy among children on the basis of duration of overlap between two or more psychotropic medications.

<http://www.ncbi.nlm.nih.gov/pubmed/22193792> (Abstract)

Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program.

Constantine RJ, Boaz T, Tandon R.

Clinical Therapeutics 2010;32(5):949–59.

The aims of this study were to quantify and describe antipsychotic polypharmacy use among patients aged 6–12 years (children) and 13–17 years (adolescents) and to identify the characteristics of polypharmacy recipients.

<http://www.ncbi.nlm.nih.gov/pubmed/20685503>

Predictors of polypharmacy and off-label prescribing of psychotropic medications: A national survey of child psychiatrists

Marcia Kearns

Thesis – Master of Arts 2011, University of Missouri

A national survey of child psychiatrists to examine typical prescribing practices for children with anxiety, depression, and disruptive behavior disorders from a social judgment theory perspective. The author examined the extent to which polypharmacy and off-label prescribing occur in routine practice and the degree to which child characteristics, child psychiatrist characteristics, and medication availability may influence these prescribing practices.

<https://mospace.umsystem.edu/xmlui/bitstream/handle/10355/11178/research.pdf.pdf?sequence=3> (Full text)

National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007.

Comer JS, Olfson M, Mojtabai R.

Journal of the American Academy of Child & Adolescent Psychiatry. 2010;49(10):1001–10.

Analysis of the annual data from the 1996–2007 National Ambulatory Medical Care Surveys that examined patterns and trends in multi-class psychotropic treatment within a nationally representative sample of 3466 child and adolescent visits to office-based physicians in which a psychotropic medication was prescribed.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952543/> (Abstract)

Pediatric Psychotropic PolypharmacyZonfrillo MR, Penn JV, Leonard HL. *Psychiatry (Edgmont (Pa.: Township) 2005 Aug;2(8):14-9.*

A literature review of relevant articles pertaining to polypharmacy using the Pub Med database from 1994 through April 2004 for pediatric populations under 18 years old.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000211/> (Abstract)

Disease Specific Polypharmacy***Depression*****Medication Augmentation after the Failure of SSRIs for Depression**

Madhukar H. Trivedi, Maurizio Fava, Stephen R. Wisniewski, Michael E. Thase, Frederick Quitkin, Diane Warden, Louise Ritz, Andrew A. Nierenberg, Barry D. Lebowitz, Melanie M. Biggs, James F. Luther, Kathy Shores-Wilson,

A. John Rush, for the STAR*D Study Team *New England Journal of Medicine* 2006;354:1243–52.

This study might be considered a “real-world” trial of the augmentation of an SSRI—citalopram—with sustained-release bupropion or buspirone after a consistent, well-implemented trial of citalopram was performed. Remission rates in this trial were similar to those found in most previous uncontrolled trials of augmentation

of SSRIs, which have typically been conducted in research clinics and have involved symptomatic volunteers with nonchronic depression and few general medical and psychiatric coexisting illnesses. Remission rates in this trial should be generalizable to most outpatients with nonpsychotic major depressive disorder who are seen in both primary and psychiatric settings and who have not had adequate benefit with the use of an SSRI alone.

<http://www.nejm.org/doi/pdf/10.1056/NEJMoa052964> (Full text).

Schizophrenia

Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P.

Archives of General Psychiatry. 2012;69(5):476–83.

In a registry based linkage study, the authors investigated if the use of benzodiazepines, antidepressants, or multiple concomitant antipsychotics is associated with increased mortality among patients with schizophrenia.

They linked national databases of mortality and medication prescriptions among a complete nationwide cohort of 2588 patients hospitalized in Finland for the first time with a diagnosis of schizophrenia between January 1, 2000, and December 31, 2007. Hazard ratios (HRs) were computed for all-cause mortality during the use of antipsychotics, antidepressants, or benzodiazepines in outpatient care,

<http://archpsyc.jamanetwork.com/article.aspx?articleid=1151489> (Abstract)

Treatment-resistant Schizophrenia: Evidence-based Strategies.

Englisch S., Zink M. *Mens Sana Monographs* 2012;10:20–32.

The authors report on findings of frequent use of polypharmacy in treatment-refractory cases, addressing psychotic positive, negative and cognitive symptoms, treatment-emergent side effects caused by antipsychotics and comorbid depressive or obsessive-compulsive symptoms.

<http://www.msmonographs.org/article.asp?issn=0973-1229;year=2012;volume=10;issue=1;page=20;epage=32;aulast=Englisch> (Full text).

Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.

Längle G, Steinert T, Weiser P, Schepp W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R.

Acta Psychiatrica Scandinavica. 2012;125(5):372–81.

The authors evaluated the effects of different types of psychotropic polypharmacy on clinical outcomes and quality of life (QOL) in patients with schizophrenia and schizoaffective disorder in routine care.

<http://www.ncbi.nlm.nih.gov/pubmed/22321029> (Abstract)

Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks

Barnes, Thomas R.E.; Paton, Carol *CNS Drugs:* 2011; 25(5) 383–399

This review addresses the clinical trial data and other evidence for the following pharmacological approaches: the addition of a second antipsychotic to boost therapeutic response, the use of as-required antipsychotic medication (mainly to treat disturbed behaviour), gradual cross-titration while switching from one antipsychotic to another, and augmentation of clozapine with a second antipsychotic where the illness has failed to respond adequately to an optimized trial of clozapine. Also reviewed are examples of systematic, practice-based interventions designed to reduce the prevalence of antipsychotic polypharmacy, most of which have met with only modest success.

http://adisonline.com/cnsdrugs/Abstract/2011/25050/Antipsychotic_Polypharmacy_in_Schizophrenia_3.aspx (Abstract)

Antipsychotic polypharmacy in the treatment of schizophrenia—a health technology assessment

Baandrup L, Lublin H, Nordentoft M, Peacock L, Srensen J, Andersen SE, Glenthj B

Copenhagen: National Board of Health, Danish Centre of Health Technology Assessment (DACEHTA), 2011.

Health Technology Assessment—funded projects 2011; 11(1)

Language: English summary of the full report in Danish

Version date: January 25 2011

This health technology assessment explored how antipsychotic polypharmacy may be reduced by intervention methods and organisational changes. The report is directed at decision-makers at the level of the management board of regions and mental health centres. This report only discusses antipsychotic polypharmacy in the context of schizophrenia spectrum disorders, because the principles of treatment regarding other psychiatric disorders, e.g. bipolar affective disorder, differ substantially.

<http://www.sst.dk/publ/Publ2011/MTV/Polyfarmaci/polyfarmaciMTVsummary.pdf> (Full text)

Combination and augmentation strategies in treatment-resistant schizophrenia

Susanne Englisch, Mathias Zink

Drug Discovery Today: Therapeutic Strategies Vol.8 (1–2) 2011, 17–23

This review discusses risks, benefits and levels of evidence of combination strategies involving multiple psychotropic substances, with a focus on their clinical relevance.

<http://www.sciencedirect.com/science/article/pii/S1740677311000313> (Abstract)

Polypharmacy in schizophrenia

Zink M, Englisch S, Meyer-Lindenberg A.

Current Opinion in Psychiatry. 2010;23(2):103–11.

This review summarizes the current state of evidence of combined antipsychotic treatment strategies and the augmentation of antipsychotics with mood stabilizers,

antidepressants and experimental substances. <http://www.ncbi.nlm.nih.gov/pubmed?term=Curr%20Opin%20Psychiatry%20AND%20Polypharmacy%20in%20schizophrenia.%20AND%20Zink%20M> (Abstract)

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S.

Schizophrenia Bulletin 2009 Mar;35(2):443–57.

This paper reports on the evaluation of therapeutic and adverse effects of antipsychotic cotreatment vs monotherapy in schizophrenia, based on Cochrane Schizophrenia Group register and hand searches of relevant journals/conference proceedings. Study Selection included randomized controlled trials comparing antipsychotic monotherapy to cotreatment with a second antipsychotic. The authors concluded that in certain clinical situations, antipsychotic cotreatment may be superior to monotherapy. However, the database is subject to possible publication bias and was too heterogeneous to derive firm clinical recommendations, underscoring the need for future research.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659301/pdf/sbn018.pdf> (Full text)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Douglas Faries, Haya Ascher-Svanum, Baojin Zhu, Christoph Correll, John Kane *BMC Psychiatry* 2005, 5:26 doi:10.1186/1471-244X-5-26

This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications. The authors concluded that despite guidelines recommending the use of polypharmacy only as a last resort, the use of antipsychotic polypharmacy for prolonged periods is very common during the treatment of schizophrenia patients in usual care settings. Reasons for and the impact of the predominant use of polypharmacy will require further study.

<http://www.biomedcentral.com/1471-244X/5/26> (Full text).

Validation of Polypharmacy Process Measures in Inpatient Schizophrenia Care

Birgit Janssen, Stefan Weinmann, Mathias Berger, Wolfgang Qaebele *Schizophrenia Bulletin*, Vol. 30, No. 4, 2004 1023–1033

As part of a comprehensive quality management program, the authors prospectively evaluated two schizophrenia polypharmacy performance measures in a cohort of 1,075 consecutively recruited individuals with schizophrenia in seven psychiatric hospitals. The results show the strengths and limits of polypharmacy performance measures to compare clinical practice in inpatient schizophrenia care and to detect possible treatment problems.

<http://schizophreniabulletin.oxfordjournals.org/content/30/4/1023.full.pdf> (Full text)

Polypharmacy in patients with schizophrenia.

McCue RE, Waheed R, Urcuyo L. *Journal of Clinical Psychiatry*. 2003 Sep;64(9):984–9.

The objective of this report was to describe the changes in prescription practices with psychotropic medications for patients diagnosed with schizophrenia in 1995 and 2000. No patients were discharged on treatment with more than 1 antipsychotic in 1995, whereas in 2000, 15.9 % of patients were. Results of increased use of polypharmacy are discussed.

<http://www.ncbi.nlm.nih.gov/pubmed/14628972> (Abstract)

General Practice Guidelines

Handbook of Schizophrenia Spectrum Disorders, Volume III

Therapeutic Approaches, Comorbidity, and Outcomes

Michael S. Ritsner (Editor), Springer, 2011, 462 p.

This collection of monographs by eminent investigators reviews recent research regarding the origins, onset, course, and outcome of schizophrenia spectrum disorders. The book provides an up-to-date overview of the rapid advances made in the clinical and basic science studies supporting our understanding of the relationship between cerebral processes and clinical, cognitive and other presentations of the schizophrenia spectrum disorders. In addition, this book aims to monitor important research developments, relevant to the treatment and rehabilitation of patients.

<http://www.springer.com/biomed/neuroscience/book/978-94-007-0833-4>

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines

The Australian and New Zealand versions of RANZCP's Consumer and Carer Clinical Practice Guidelines are free of charge to download, using the links on the webpage. These booklets are a valuable resource to support consumers, their carers, families and friends in learning more about mental illness and the treatments that are available.

The RANZCP has developed Clinical Practice Guidelines (CPGs) to provide mental health practitioners, consumers, and carers with evidence-based information about particular mental illnesses and appropriate treatment options. Available guidelines: anorexia nervosa, bipolar disorder, deliberate self harm, depression, panic disorder and agoraphobia, schizophrenia.

<http://www.ranzcp.org/Publications/Clinical-Practice-Guidelines.aspx>

National Institute for Health and Clinical Excellence (NICE)

Guidelines—National Institute for Health and Clinical Excellence—Links to guidelines in psychiatry

<http://www.nice.org.uk/Search.do?searchText=psychiatry&newsearch=true&x=17&y=12&page=2#/search/?reload>

Borderline personality disorder Borderline personality disorder: treatment and management

NICE clinical guideline 78 Developed by the National Collaborating Centre for Mental Health

Issue date: January 2009

<http://www.nice.org.uk/nicedia/live/12125/42900/42900.pdf>

Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults

Management in primary, secondary and community care

Issue date: January 2011

<http://www.nice.org.uk/nicedia/live/13314/52599/52599.pdf>

Schizophrenia

Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care

NICE clinical guideline 82

Developed by the National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence

<http://www.nice.org.uk/nicedia/live/11786/43608/43608.pdf>

APA Practice Guidelines

<http://www.psych.org/practice/clinical-practice-guidelines>

American Psychiatric Association Clinical Practice Guidelines provide evidenced—based recommendations for the assessment and treatment of psychiatric disorders. The guidelines are published on PsychiatryOnline. Below are direct links to guidelines for some of the major psychiatric disorders.

Schizophrenia

Guideline Watch (September 2009): Practice guideline for the treatment of patients with schizophrenia

Dixon L, Perkins D, Calmes C.

The original guideline was published in February 2004. The November 2009 Guideline Watch associated with this guideline provides additional information that has become available since publication of the guideline, but it is not a formal update of the guideline.

http://psychiatryonline.org/data/Books/prac/Schizophrenia_Guideline%20Watch.pdf

Major Depressive Disorder

Practice guideline for the treatment of patients with major depressive disorder, Third Edition

Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, Van Rhoads, RX

American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA); 2010 Oct. 152 p. (1170 references)

<http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485>

Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition

Robert M. A. Hirschfeld

APA's *Practice Guideline for the Treatment of Patients With Bipolar Disorder*, 2nd Edition, was published in April 2002 (1). Since that time, a number of controlled treatment studies on aspects of bipolar disorder have been completed and published. This guideline watch briefly reviews the most important of the studies. The majority of the studies were industry supported.

<http://psychiatryonline.org/data/Books/prac/Bipolar.watch.pdf>

Practice guideline for the Treatment of Patients With Obsessive-Compulsive Disorder

Koran, LM, Hanna GL, Hollander E, Nestadt G, Simpson HB.

This practice guideline was approved in October 2006 and published in July 2007

<http://psychiatryonline.org/data/Books/prac/OCDPracticeGuidelineFinal05-04-07.pdf>

U.S. Department of Health & Human Services, Agency for Healthcare Research and Quality**National Guideline Clearinghouse—Guidelines for Mental Disorders**

Includes 292 links to clinical practice guidelines from around the globe, for various mental disorders

<http://guideline.gov/browse/by-topic-detail.aspx?id=1180&ct=1>

Appendix 2. List of Psychotropic Medications

Rena Kurs

Abstract The following is a list of psychotropic medications arranged in alphabetical order, by generic names. The list is divided into the following subsections: Antipsychotic agents, Antidepressant Medications (also used for anxiety disorders), Mood Stabilizing and Anticonvulsant Medications, Anti-anxiety Medications, Sleep Agents

This list was compiled for the convenience of the reader. It is not intended or implied to be a substitute for professional medical or pharmacological advice. The information on psychotropic medications in this list is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information is not intended to be patient education, and should not be used as a substitute for professional diagnosis and treatment. Following the psychotropic drug list, there is an annotated list of internet links to sites with current psychotropic drug lists that include additional information such as dosage facts, recommended dosages/blood levels, half life, anticholinergic effects, sedation, orthostatic hypotension, sexual dysfunction, gastrointestinal effects, activation/insomnia, detailed side effects, medication management and black box warnings.

Keywords Psychotropic drugs • Generic drugs • Trade names • Brand names • Therapeutic class • Chemical Class Abbreviations

Abbreviations

FGA 1st generation antipsychotic agent
MAOI Monoamine oxidase inhibitor
MAOI-B Monoamine oxidase -B inhibitor

R. Kurs, B.A. (✉)

Medical Library, Sha'ar Menashe Mental Health Center, Hadera, Israel
e-mail: rena@sm.health.gov.il

SGA	2nd generation antipsychotic agent
SNRI	Serotonin norepinephrine reuptake inhibitor
SPARI	Selective partial agonist and reuptake inhibitor
SSRI	Selective serotonin reuptake inhibitor
TCA	Tricyclic antidepressant

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Aripiprazole	Abilify, Abilitat, Abilify Discmeltv	SGA	Benzisoxazole derivatives
Asenapine	Saphris	SGA	Dibenzo-oxepino pyrroles
Chlorpromazine	Largactil, Contomin, Thorazine, Propaphenin, Megaphen, Chlorderazin, Chlorpromazine, Aminazine, Fenactil, Clozine	FGA	Phenothiazine
Clozapine	Clozaril, Leponex, FazaClo, Clopine	SGA	Dibenzodiazepine
Fluphenazine	Anatensol, Fludecasin, Dapotum D, Fludecate	FGA	Phenothiazine antipsychotics
Haloperidol	Aloperidol, Eukystol, Aloperidin, Aloperidolo, Brotopon, Galoperidol, Halopoidol, Serenace	FGA	Phenyl-piperidinybutyrophenone
Iloperidone	Zomaril, Fanapt, Fanapta, Fiapta	SGA	Piperidinyl-benzisoxazole derivatives
Loxapine	Clozapine, Dibenzoazepine, Oxilapine, Dibenzacepin, Loxapin, Loxapac	Tricyclic antipsychotic agents has been classed as FGA and SGA	Dibenzoxazepine
Lurasidone	Latuda	SGA	Benzisothiazol derivatives.
Molindone*	Moban, Molindone, Molindone Hydrochloride Tablets	Has been classed as both FGA and SGA	Dihydroindolone compound
Olanzapine	Zyprexa, Zyprexa Zydis, Olansek, Symbyax, Zalasta, Lanzac, Zyprexa Velotab	SGA	Thienobenzodiazepine class
Paliperidone	Invega, Paliperidone	SGA	Benzisoxazole derivatives
Perphenazine	Trilafon, Perfenazine, Etoperazine, Etoperazin, Ethaperazine, Fentazin, Perphenazin, Chlorpiprazine, Thilatazin	FGA	Piperazinyl phenothiazine

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Pimozide (for Tourette's syndrome)	Orap, Opiran, Neoperidole, Halomonth, Pimozidum	FGA	Diphenylbutylpiperidine
Quetiapine	Seroquel, Quetiapine fumarate	SGA	Dibenzothiazepine derivatives
Risperidone	Risperdal, Risperidal, Rispolept, Risperin, Rispolin, Sequinan, Risperdal Consta, Risperidonum, Risperdal M-Tab	SGA	Benzisoxazole derivatives
Thioridazine	Mellaril, Melleril, Meleril, Mallorol, Malloryl, Mellerets, Mellerette, Melleretten, Thioridazin, Novoridazine, Thiori	FGA	Phenothiazine
Thiothixene	Tiotixene, cis-Thiothixene, Navane, (E)-Thiothixene, Thiothixine, Navan, trans-Thiothixene	FGA	Thioxanthene derivative
Trifluoperazine	Trifluoperazine, Trifluoroperazine, Triperazine, Triflurin, Trifluoperazin, Trifluoperazina, Flurazine, Stelazine, Eskazine, Jatroneuroal, Modalina Trifluoromethylperazine	FGA	Phenothiazine
Ziprasidone	Geodon, Zeldox, Zipfasidone Hydrochloride	SGA	Benzisoxazole derivatives
<i>Antidepressant medications (also used for anxiety disorders)</i>			
Amitriptyline	Damilen, Elavil, Triptanol, Flavyl, Lantron, Seroten, Damitriptyline, Proheptadiene, Tryptanol, Tryptomer, Tryptizol, Laroxyl, Sarotex, Lentizol, Endep, Vanatrip	TCA	Dibenzocycloheptadiene derivative
Amoxapine	Asendin, Demolox, Amoxepine, Moxadil, Desmethylloxapin, Amoxapina, Amoxapinum, Asendis, Defanyl, Amoksian, Demolox, Asendin	TCA	Dibenzoxazepine class
Bupropion	Bupropion hydrochloride, Wellbutrin, Zyban, Wellbutrin SR, Wellbutrin XL, Amfebutamone hydrochloride	Unicyclic antidepressant	Aminoketones
Citalopram	Nitalapram, Cipram, Celexa, Citalopramum, Cytalopram, Celapram, Ciprapine, Citabax	SSRI	Racemic bicyclic phthalane derivative

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Clomipramine	Clomipramine hydrochloride, Anafranil, Clomipramine HCL, Anaphranil, Chlorimipramine hydrochloride	TCA	Dibenzazepine
Desipramine	Desipramine hydrochloride, Norpramin, Pertofran, Pertofrane, Norpolake, Nortimil, DMI hydrochloride, Pertofrin, Petylyl	TCA	Dibenzazepine
Desvenlafaxine	Pristiq extended release,	SNRI	
Doxepin	Doxepine, Zonalon, Quitaxon, Doxepinum	TCA	Dibenzoxepin
Duloxetine	Cymbalta, Yentreve, Xeristar Ariclaim, Duzela	SNRI	Naphthalenes
Escitalopram	Escitalopram, Cipralext, Seroplex, Nexito, anxiset-E, Lexapro, Lexamil, Lexam, Entact, Losita, Animaxen	SSRI	Furancarboxitrile
Fluoxetine	Prozac, Fluctin, Flunirin, Fluoxeren, Sarafem, Adofen, Lovan, Equibrane, Rowexetina, Fontex, Fluval	SSRI	Phenylpropylamines
Fluvoxamine	Luvox, Faverin, Dumyroxt, Dumiroxt, Favoxil, Floxyfral, Maveral	SSRI	2-aminoethyl oxime ethers of aralkylketones
Imipramine	Imidobenzyle, Antideprin, Melipramine, Berkomine, Dimipressin, Melipramin, Intalpram, Nelipramin, Dynaprin	TCA	Dibenzazepines and derivatives
Imipramine pamoate	Tofranil-PM	TCA	Dibenzazepines and derivatives
Isocarboxazid	Isocarbonazid, Isocarboxazide, Benazide, Enerzer, Marplan, Isocarboxazide, Isocarboxyzid, Maraplan, Marplon	MOAI	Hydrazine
maprotiline	Dibencycladine, Deprilept, Maprotilin, Maprotylina, Ludiomil	TCA	anthracenes
Mirtazapine	Remergil, Remeron, Zispin, Remergon, Rexer, Remeron SolTab, Mepirzepine, Promyrtil, Norset	TCA	Piperazino-azepine

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Nefazodone*	Dutonin, Serzone	Synthetically derived phenylpiperazine antidepressant	Phenols and derivatives
Nortriptyline	Sensaval, Avantyl, Noritren, Pamelor, Ateben, Desitriptilina, Nortryptiline, Nortrilen, Demethylamitriptyline, Aventyl, Lumbeck	TCA	Dibenzocycloheptenes
Paroxetine	Paxil, Seroxat, Aropax, Paxil CR, Paroxetinum, Frosinor, Motivan, Paroxetina, Paxetil	SSRI	Phenylpiperidine
Paroxetine mesylate	Pexeva	SSRI	Mesylate salt of a phenylpiperidine compound
Phenelzine	Phenelzine sulfate, Estinerval, Nardelzine, Kalgan, Nardil, Alacine, Alazine, Alazin	MAOI	Hydrazine
Protriptyline	Amimetilina, Vivactil, Protryptiline, Triptil, Novopramine, Protriptilina, Protriptylinum, Rhotrimine	TCA	Dibenzocycloheptene
Selegiline	Eldepryl, Emsam, Jumex, L-Deprenalin, Carbex, Zelapar, Selegilinum, Selegilina, Selegiline, Anipryl,	MAOI-B	Levorotatory acetylenic derivative of phenethylamine
Sertraline	Sertraline hydrochloride, Zoloft, Gladem, Serad, Lustral, Atruline, Tresleen, Tatig	SSRI	Tametralines
tranlycypromine	Parnate, Transamine, Jatrosom, Tranlycypromine	MAOI	phenethylamine and amphetamine class
Trazodone	Desyrel, Oleptro, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico, and Mesyrel	SARI	Triazolopyridine
Trimipramine	Surmontil, Rhotrimine, Stangil, Trimeprimine, Sapilent, Surmontil, Surmontyl, beta-Methylimipramine, Trimeproprimin, Stangyl,	TCA	Dibenzazepines and Derivatives

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Venlafaxine	Elafax, Venlafaxina, Venlafaxinum, Effexor, Efectin, VenlafaxineXR	SNRI	Phenols and derivatives
Vilazodone	Vibryd	SPARI	Carboxamide derivative
<i>Mood stabilizing and anticonvulsant medications</i>			
Carbamazepine	Tegretol, Carbamazepin, Finlepsin, Carbazepine, Tegretal, Neurotol, Biston, Epitol	Anticonvulsant	Dibenzazepines and Derivatives
Divalproex sodium (valproic acid)	Depakote, Epival, Valproate semisodium, Depakote ER, Sodium divalproate, Divalproate, Delepsine, Sprinkle, Valcote, Zalkote	Anticonvulsant	
Gabapentin	Neurontin, Gabapentine, Aclonium, Fanatrix, Horizant, Gabarone, Gralise, Nupentin	Anticonvulsant.	GABA analogue
Lamotrigine	Lamictal, Lamotrigine	Anticonvulsant.	Phenyltriazine
Lithium carbonate	Eskalith, Lithobid, Dilithium carbonate, Lithonate, Liskonum, Lithane, Lithotabs, Micalith, Priadel, Limas	Mood-stabilizing agent	Inorganic ions and gases
Lithium citrate (generic only)	Lithium citrate, Trilithium citrate Demalit, Litarex, Eskalith	Mood-stabilizing agent	
Oxcarbazepine	Trileptal, Oxcarbamazepine, Timox, Epilexter	Anticonvulsant and mood stabilizer	Structural derivative of carbamazepine
Topiramate	Topamax, Epitamax, Topimax, Topomax, Topina, Tipiramate	Anticonvulsant.	Sulfamate- substituted monosaccharide
<i>Anti-anxiety medications</i>			
Alprazolam	Xanax, Trankimazin, Cassadan, Esparon, Tafil, Xanax XR, Alpronax, Intensol, Tranquinal	Antianxiety and sedative- hypnotic	Triazolobenz odiazepine compound
Buspirone	BuSpar, Ansial, Buspirona, Buspironium, Bespar, Ansiced, Anxiron, Buspisal	Anxiolytic agent	Azaspirodec anedione
Chlordiazepoxide	Librium, Chlozepid, Elenium, Helogaphen, Ifibrium, Kalmocaps, Librelease, Librinin	Anxiolytic agent	Benzodiazepine
Clonazepam	Klonopin, Rivotril, Clonex, Paxam, Kriadex, Antelepsin, Cloazepam, Iktorivil, Klonopin, Landsen	Anxiolytic, anticonvulsant, muscle- relaxant	Benzodiazepine

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Clorazepate	Tranxene, Novo-Clopat	Anxiolytic, anticonvulsant, muscle-relaxant	Benzodiazepine
Diazepam	Valium, Ansiolisina, Assival, Diazemuls, Relanium, Stesolid, Apaurin, Faustan, Seduxen, Sibazon	Anticonvulsant, anxiolytic, sedative, muscle relaxant	Benzodiazepine
Lorazepam	Ativan, Temesta, Idalprem, Tavor, Bonatranquan, Delormetazepam, Almazine	Anti-anxiety agent hypnotic, anticonvulsant, sedative	Benzodiazepine
Oxazepam	Adumbran, Tazepam, Serax, Vaben, Ansioacepam, Droxacepam, Anxiolit, Aplakil, Astress, Drimuel	Anti-anxiety, alcohol withdrawal, and insomnia	Benzodiazepine
ADHD medications			
Amphetamine	Mydril, Adderall, dexedrine, Dextrostat, Desoxyn, Didrex, ProCentra, Fenopromin, Vivanxe, Benzedrine, Psychedrine	CNS stimulant	Phenethylamine
Atomoxetine	Strattera, Tomoxetine, Attentin	Non stimulant SNRI	Phenylpropylamines
Dexamethylphenidate	Focalin	CNS stimulant	
Dextroamphetamine	Dexedrine, Dextrostat, Dexamphetamine	CNS stimulant	Phenethylamines Amphetamines
Guanfacine	Intuniv, Estulic, Tenex, Guanfacinum, Guanfacina	Centrally acting antihypertensive agent	Phenethylamines
Lisdexamfetamine dimesylate	Vyvanse, Lisdexamfetamine mesilate	CNS stimulant	Phenethylamines amphetamines
Methamphetamine	Desoxyn, Desyphed, Metamphetamine, Norodin, Stimulex	CNS stimulant	Phenethylamines amphetamines
Methylphenidate	Ritalin, Concerta, Daytrana, Metadate, Methylin, Rhiphenidate, Ritaline, Meridil,	CNS stimulant	Adrenergic agent, dopamine uptake inhibitors, adrenergic uptake inhibitors,
Sleep agents			
Eszopiclone	Estorra, Lunesta	Hypnotic	Lactams, cyclopyrrolones
Ramelteon	Roserem	Hypnotic	Benzofurans, indanes, phenylpropylamines

(continued)

(continued)

Antipsychotic agents			
Generic name	Trade/Brand names	Therapeutic class	Chemical class
Zaleplon	Sonata, Zalaplone	Hypnotic	Acetanilides, pyrazolopyrimidines
Zolpidem	Ambien CR, Lorex, Stilnoct, Stilnox, Sanval	Hypnotic	Phenylpiperones, imidazopyridines

*Medications discontinued in some countries

Bibliography

1. Mental Health Medications. National Institute of mental Health
<http://www.nimh.nih.gov/health/publications/mental-health-medications/complete-index.shtml#pub11>
2. PubChem Compound
The PubChem Compound Database contains validated chemical depiction information provided to describe substances in PubChem Substance. Structures stored within PubChem Compounds are pre-clustered and cross-referenced by identity and similarity groups.
<http://www.ncbi.nlm.nih.gov/pccompound>
3. Daily Med: Current Medication Information
DailyMed provides high quality information about marketed drugs.
Drug labeling on this Web site is the most recent submitted to the Food and Drug Administration (FDA) and currently in use.
<http://dailymed.nlm.nih.gov/dailymed/>
4. DrugBank: Open Data Drug and Drug Target Database
<http://www.drugbank.ca/>
5. BehaveNet. BehaveNet is the Web's most comprehensive encyclopedic taxonomy of psychiatric drugs (including drugs of abuse), diagnoses (including diagnostic criteria), terminology and notable people with references to associated media and other resources
<http://behavenet.com/>

Links to Psychotropic Drug Lists

1. Review of Psychotropic Drugs 2012

Includes Medication categories, brand name, generic name, dosage facts, half life, anticholinergic effect, sedation, orthostatic hypotension, sexual dysfunction, GI effects, activation/insomnia, detailed side effects Authors' disclaimer: These Medication tables are NOT exhaustive for drug categories, dosage facts, side effects, adverse effects, indications or any special instructions (comments) and should only be used to guide learning. Use a pharmacologic text, drug guide such as the Physician's Desk Reference (PDR), or package insert for more complete medication information.

http://www.dhs.state.il.us/OneNetLibrary/27896/documents/By_Division/Division%20of%20DD/HumanRights/PsychotropicDrugsList.pdf

2. **Contemporary Psychotropic Medications listed alphabetically.**

Metro Crisis Services

In this table, both the generic or chemical names and the U.S. brand names are listed alphabetically. Brand names used in the United States, these medications may be sold outside the U.S. under different brand names. Includes links to Medline Plus for additional information for each drug.

<http://www.metrocrisiservices.org/7-learn-more/medications/medications-listed-alphabetically>

3. **National Alliance on Mental Illness, NAMI, Policy Research Institute**

Commonly Prescribed Psychotropic Medications

Brand names are followed by the generic in parenthesis. A second chart below provides cross-referencing by generic name.

*Although this medication has been approved by the FDA for the treatment of other disorders, it has not been approved for this particular use. Some evidence of this medication's efficacy for such use does exist however. This type of medication use is referred to as "off label."

Remember, always consult your doctor or pharmacist with any specific medication questions http://www.nami.org/Template.cfm?Section=Policymakers_Toolkit&Template=/ContentManagement/HTMLDisplay.cfm&ContentID=18971

4. **University of Illinois at Chicago, Department of Children and Family Services (DCFS) Psychotropic Medication List**

Includes Generic name, trade name, recommended doses/blood levels, medication management, black box warning, FDA indication for children

http://www.psych.uic.edu/csp/DCFS_Psychotropic_Medication.pdf

5. **National Institute of Mental Health**

This guide describes the types of medications used to treat mental disorders, side effects of medications, directions for taking medications, and includes any FDA warnings. <http://www.nimh.nih.gov/health/publications/mental-health-medications/complete-index.shtml>

6. **International Narcotics Control Board. Green List (24th edition, May 2010)**

Annex to the annual statistical report on psychotropic substances (form P). List of Psychotropic Substances under International Control

http://www.incb.org/pdf/e/list/Green_list_ENG_2010_53991.pdf

7. **Medication Safety team, Department of Health, Australia. Psychotropic Drug List**

Current at January 2011.

This is a list of psychotropic medications available in Australia.

This table has been developed in collaboration with the Medication Safety team, Department of Health. For ease of uses, the medications are listed alphabetically, whether by generic name, or by brand name.

http://www.fallssa.com.au/documents/hp/Drug_list_in_SA_Health_Template_V2.pdf

Contents to Volume II

Part I Antipsychotic Polypharmacy

1 Antipsychotic Polypharmacy in Schizophrenia: ‘Secret Sauce or Wild Abandon?’	3
Peter F. Buckley	
2 Antipsychotic Polypharmacy in USA	11
Anand K. Pandurangi and John T. Vernon	
3 Antipsychotic Polypharmacy in Czech Republic and in Ukraine	31
Viktor P. Samokhvalov, Oxana E. Samokhvalova, Viktoria A. Verbenko, and Georgij N. Verbenko	
4 Antipsychotic Polypharmacy in Residential Facilities in Italy: The Gap Between Recommendations and Real World Practice.....	43
Lucio Ghio, Werner Natta, Simona Gotelli, and Luigi Ferrannini	
5 Antipsychotic Polypharmacy and Associated Phenomena in Patients with Schizophrenia: Rational or Irrational?	61
Yong K.H. Michael, Norman Sartorius, and Kang Sim	
6 Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?.....	81
Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, and Masaru Mimura	
7 Clozapine Combinations in Treatment-Resistant Schizophrenia Patients	109
Vladimir Lerner and Chanoch Miodownik	
8 Metabolic Syndrome and Antipsychotic Polypharmacy	145
Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, and Hiroto Ito	

Part II Polypharmacy for Other Psychiatric Conditions

9 Evidence Based Combination Therapy for Bipolar Disorder	159
Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, and Konstantinos N. Fountoulakis	
10 Antidepressant Combination Strategies for Major Depressive Disorder	179
André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, and Roger S. McIntyre	
11 Herbal Remedies and Nutraceuticals as Augmentation or Adjunct for Mood and Anxiety Disorders: Evidence for Benefit and Risk	191
Arun V. Ravindran and Tricia L. da Silva	
12 Obsessive-Compulsive Syndromes in Schizophrenia: A Case for Polypharmacy?	233
Frederike Schirmbeck and Mathias Zink	
13 Polypharmacy and Potentially Inappropriate Medication Use Among Elders with Dementia	263
Jan Luzny	
14 The Role of Polypharmacy in Bipolar Disorder Treatment Guidelines	275
Heinz Grunze	
Appendix 1. Annotated Bibliography on Polypharmacy	289
Rena Kurs	
Appendix 2. List of Psychotropic Medications	301
Rena Kurs	

Contributors to Volume II

Peter F. Buckley M.D. Department of Psychiatry and Health Behavior, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA, USA

André F. Carvalho, M.D., Ph.D. Department of Clinical Medicine and Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil

Tricia L. da Silva, M.A. Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Toronto, ON, Canada

Luigi Ferrannini, M.D. Department of Mental Health, ASL3 Genovese, Genoa, Italy

Konstantinos N. Fountoulakis, M.D., Ph.D. 3rd Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Lucio Ghio, M.D. Department of Neuroscience, Ophthalmology and Genetic, Psychiatry Section, University of Genoa, Genoa, Italy

Xenia Gonda Department of Clinical and Theoretical Mental Health, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Simona Gotelli, M.D. Department of Neuroscience, Ophthalmology and Genetic, Psychiatry Section, University of Genoa, Genoa, Italy

Heinz Grunze Institute of Neuroscience, Academic Psychiatry, Campus of Aging and Vitality, Wolfson Research Centre, Newcastle University, Newcastle, UK

Thomas N. Hyphantis, M.D., Ph.D. Department of Psychiatry, Medical School, University of Ioannina, Ioannina, Greece

Apostolos Iacovides 3rd Department of Psychiatry School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Hiroto Ito Department of Social Psychiatry, National Institute of Mental Health, Tokyo, Japan

Rena Kurs, B.A. Medical Library, Sha'ar Menashe Mental Health Center, Hadera, Israel

Vladimir Lerner, M.D., Ph.D. Ministry of Health, Faculty of Health Sciences, Ben Gurion University of the Negev and Be'er Sheva Mental Health Center, Be'er Sheva, Israel

Jan Luzny, M.D. Mental Hospital Kromeriz and Palacky University Olomouc, Praha, Czech Republic

Danielle S. Macêdo, Ph.D. Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil

Stamatia Magiria 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Roger S. McIntyre, M.D., FRCPC Department of Psychiatry, University of Toronto, Toronto, ON, Canada

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada

Yong K. H. Michael, M.D., M.Med (Psychiatry) Department of Psychological Medicine, Jurong Health Alexandra Hospital, Singapore, Singapore

Masaru Mimura, M.D., Ph.D. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

Chanoch Miodownik, M.D. Ministry of Health, Faculty of Health Sciences, Ben Gurion University of the Negev and Be'er Sheva Mental Health Center, Be'er Sheva, Israel

Fuminari Misawa Yamanashi Prefectural KITA Hospital, Yamanashi, Japan

Werner Natta, M.D. Department of Neuroscience, Ophthalmology and Genetic, Psychiatry Section, University of Genoa, Genoa, Italy

Yasuyuki Okumura Department of Social Psychiatry, National Institute of Mental Health, Tokyo, Japan

Anand K. Pandurangi, MBBS, M.D. Division of Inpatient Psychiatry, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA

Schizophrenia Program and Brain Stimulation Therapies Program, Virginia Commonwealth University, Richmond, VA, USA

Arun V. Ravindran, MBBS, M.Sc., Ph.D., FRCPC, FRCPsych. Departments of Psychiatry, Psychology and Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada

Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Toronto, ON, Canada

Oxana E. Samokhvalova, M.D., Ph.D. Department of Psychiatry, Central Military Hospital – Military University Hospital Prague, Prague, Czech Republic

Viktor P. Samokhvalov, M.D., Ph.D., D.Sc. Deutsch-Russische Gesellschaft für Psychiatrie, Psychotherapie und psychosoziale Gesundheit, Nürnberg, Germany

Norman Sartorius, M.D., Ph.D. Association for the Improvement of Mental Health Programmes, Geneva, Switzerland

Frederike Schirmbeck, Dipl.-Psych Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany

Melina Siamouli 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Kang Sim, MBBS (Melb), M.Med (Psychiatry), PG Dip Psychotherapy (Distinction) Institute of Mental Health (IMH), Singapore, Singapore

Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Takefumi Suzuki, M.D., Ph.D. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

Inokashira Hospital, Tokyo, Japan

Hiroyuki Uchida, M.D., Ph.D. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

Georgij N. Verbenko, M.D. Department of Psychiatry, Crimean Medical University, Simferopol, Crimea, Ukraine

Viktoria A. Verbenko, M.D., Ph.D. Department of Psychiatry, Crimean Medical University, Simferopol, Crimea, Ukraine

John T. Vernon, M.D. Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA

Koichiro Watanabe, M.D., Ph.D. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan

Fujii Yasuo Yamanashi Prefectural KITA Hospital, Yamanashi, Japan

Mathias Zink, M.D. Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany

Index

A

Acetylsalicylic acid, 186, 187
Adjunct, 167, 172, 174, 176, 183, 185, 194, 249
Adverse drug reactions, 46, 47, 65–67, 248
Affective symptoms, 109, 111, 169, 171
Aggressive symptoms, 109, 112
Agranulocytosis, 15, 115, 120
Alcohol, 19, 46, 48, 54, 57, 140, 169, 171, 177, 273
Allopurinol, 189, 195
Alprazolam, 63, 71, 176, 195, 249, 272
Alzheimer's disease (AD), 7, 55, 192
Amisulpride, 81, 144, 145, 250, 251
Anemia, 185
Anhedonia, 109, 190, 213, 215
Anti-dementia drugs, 171
Antiepileptic drug, 163, 171, 172, 175, 235, 238, 250
Antipsychotic, 7, 25–40, 46, 75–99, 107–124, 131, 137–152, 158, 212, 235, 250
Antipsychotic polypharmacy, 75–99, 107–124, 139, 141, 144, 146–148, 150, 152, 159, 160, 256, 258, 260–262
Anxiety disorders, 151, 171, 177, 181, 246, 264, 269
Aripiprazole, 6, 8, 28, 29, 47, 49, 63, 69, 78, 80, 81, 120, 122–123, 172, 251, 268
Asenapine, 8, 28, 29, 56, 69, 120, 123, 268
Asthenia, 185
Augmentation, 5, 6, 14, 18, 19, 80, 88–91, 139–141, 149–152, 160, 163–169, 171–175, 182, 184, 185, 187, 191–193, 195, 196, 213, 223–225, 243–251, 256, 257, 259, 261
Australia, 275

B

BDNF. *See* Brain-derived neurotrophic factor (BDNF)
Benzodiazepines, 17, 22, 48, 49, 52, 54, 63, 71, 94, 95, 151, 160, 162–164, 171, 175–177, 221, 256, 260, 268, 272, 273
Bexarotene, 185, 195
Bipolar, 5, 6, 9, 10, 18, 21, 95, 97, 171, 235, 257, 261, 263, 265
Bipolar disorder, 5, 6, 10, 18, 97, 171, 235, 257, 263, 265
Body mass index (BMI), 176
BPRS. *See* Brief psychiatric rating scale (BPRS)
Brain-derived neurotrophic factor (BDNF), 170, 193, 234, 235
Brand names, 8, 268–275
Brief psychiatric rating scale (BPRS), 91, 173, 175
Bupropion, 9, 12, 14, 15, 19, 49, 54, 61, 63, 65, 70, 165, 168, 224, 249, 259, 269
Buspirone, 19, 52, 63, 168–169, 214, 259, 272

C

Canada, 79, 80, 94
Carbamazepine, 5, 6, 8, 18, 52, 59, 61–63, 65, 67, 70, 131, 151, 170–173, 175, 195, 235, 237, 238, 272
Cardiac effects, 224
CATIE. *See* Clinical antipsychotic trials of intervention effectiveness (CATIE)
CBT. *See* Cognitive behavioral therapy (CBT)
Celecoxib, 186, 187, 195, 249

Central nervous system (CNS), 5, 7, 48, 49, 53, 54, 160, 175, 181, 182, 247, 249–251, 260, 273

Chemical class, 268–274

Chlorpromazine, 48, 54–56, 63, 65, 70, 77, 223, 224, 268

Clinical antipsychotic trials of intervention effectiveness (CATIE), 79, 88, 150, 151, 164, 169, 176, 213

Clinical global impression (CGI) scale, 166, 221

Clozapine, 11, 15, 19, 28, 29, 55, 56, 61–63, 65, 69, 76–78, 80, 88–92, 98, 99, 115, 117, 120–121, 138, 139, 144–146, 174, 175, 177–180, 212, 215, 218, 220, 223, 224, 226, 261, 268

CNS. *See* Central nervous system (CNS)

Cognitive behavioral therapy (CBT), 94, 178, 247

Cognitive impairment, 53–55, 85, 87, 88, 163, 187, 190, 219, 220, 223

Cognitive symptoms, 27, 39, 78, 109, 159, 166, 167, 178, 179, 213, 214, 219–220, 260

Combination, 5, 27, 46, 76, 128, 138, 159, 213, 249

Complementary, 46

Compulsive, 17, 168, 260

Counteraction, 86

Cyclooxygenase-2 inhibitor, 186

CYP450. *See* Cytochrome P450 (CYP450)

Cytochrome P450 (CYP450), 59–62, 64–70, 111, 121

Czech Republic, 280, 281

D

D-amphetamine, 190

D-cycloserine, 177–180

Defined daily doses (DDD), 140, 143, 145

Dehydroepiandrosterone (DHEA), 181, 182, 195

Dehydroepiandrosterone sulfate (DHEAS), 181, 193

Delusions, 54, 109, 173, 175–178, 247

Dementia, 171, 183, 187, 188

Dependence, 169, 177, 190

DHEA. *See* Dehydroepiandrosterone (DHEA)

DHEAS. *See* Dehydroepiandrosterone sulfate (DHEAS)

Diagnostic hierarchy, 9, 12

Diazepam, 62, 63, 71, 176, 273

Donepezil, 8, 188, 195

Dopamine, 12, 26, 47, 108, 145, 158, 215, 239

Dopamine pathway, 109

Double-blind trial, 179, 184

Drug-drug interactions, 15, 21, 47, 118, 121

D-serine, 177–180, 195

Dyslipidemia, 7, 224

E

EEG. *See* Electroencephalograph (EEG)

Eicosapentaenoic acid (EPA), 192

Elders, 15, 21, 54, 55, 66, 166, 182

Electroencephalograph (EEG), 168, 173, 234, 235, 238, 239

England, 259

EPA. *See* Eicosapentaenoic acid (EPA)

Epilepsy, 171, 234, 235, 237–240

EPS. *See* Extrapyramidal side effects (EPS); Extrapyramidal symptoms (EPS)

Escitalopram, 8, 14, 15, 56, 62, 63, 167, 251, 270

Estrogen, 180–184

Excitotoxicity, 12, 183

Extrapyramidal side effects (EPS), 51, 53–54, 77, 86, 90, 92, 114, 119, 152, 164, 214

Extrapyramidal symptoms (EPS), 7, 77, 79, 111, 113, 121–123, 152, 163, 219, 221, 224, 225

F

FES. *See* First-episode schizophrenia (FES)

FGAs. *See* First generation antipsychotics (FGAs)

Finland, 169, 176, 260

First-episode schizophrenia (FES), 118, 143, 187, 217

First generation antipsychotics (FGAs), 70, 109, 128, 167, 183, 188, 212, 214–220, 224–226

Fluoxetine, 8, 56, 62, 63, 65, 68, 166, 195, 250

Fluphenazine, 70, 268

Fluvoxamine, 62, 63, 166, 195, 270

G

GABA. *See* γ -amino-butyric acid (GABA)

Gabapentin, 64, 171, 238, 249, 250, 272

Galantamine, 8, 187, 188, 195

γ -amino-butyric acid (GABA), 15, 48, 54, 151, 162, 166, 171, 172, 176, 181, 234, 239, 240, 272

Generalized anxiety disorder, 181
 Germany, 129, 132
 Glycine, 177–180, 195
 Guidelines, 14, 21, 22, 76, 82, 85, 86, 93, 95,
 111, 117, 139–141, 143, 145, 146,
 148, 151, 152, 159, 161, 164, 213,
 217, 256–258, 262–265

H

Hallucinations, 54, 109, 172, 173, 175–177
 Haloperidol, 21, 39, 48, 49, 55, 56, 62, 63, 65,
 70, 77, 78, 82, 98, 144–146, 166,
 190, 214, 218, 219, 224, 268
 Headache, 9, 50, 185, 191, 222, 236, 245, 250
 Herbal compounds, 46, 49, 51, 67, 257
 High-dose, 87, 108, 115, 117, 119, 123, 161
 Histamine, 47, 54, 55, 214, 248, 249
 Hormone, 21, 160, 184, 185, 195, 213, 249
 HPA. *See* Hypothalamic-pituitary-adrenal
 axis (HPA)
 Hypertension, 7, 49–50, 52, 159, 191
 Hypnotics, 8, 54, 138, 148, 151, 152, 163,
 164, 177
 Hypothalamic-pituitary-adrenal
 axis (HPA), 181
 Hypothyroidism, 185

I

Iloperidone, 8, 28, 29, 56, 69, 120, 123, 268
 Inpatients, 79, 80, 82–84, 86, 87, 94–96, 140,
 141, 146, 147, 151, 160, 163, 164,
 167, 173, 179, 187, 192, 262

J

Japan, 80, 88, 164, 176

L

Lamotrigine, 5, 8, 70, 151, 170–175, 235,
 238, 272
 Leucopenia, 185
 Limbic, 34, 40, 162, 234, 235, 238, 239
 Lipid abnormalities, 92, 185
 Lithium, 16, 19, 21, 22, 52, 56, 64, 67–69,
 151, 160, 163, 170–171, 195, 213,
 235, 237, 272
 Long-term patients, 95
 Loxapine, 268
 L-theanine, 192–193, 195
 Lurasidone, 8, 28, 29, 69, 120, 123, 268

M

Magnesium, 58
 Major depressive disorder (MDD), 7, 9, 14,
 18, 19, 168, 213, 219, 222, 246,
 260, 264
 Mania, 7, 170
 Manic, 21, 83, 84, 170, 235
 Manic-depression, 170
 MAOI. *See* Monoamine oxidase inhibitor
 (MAOI)
 MDD. *See* Major depressive disorder (MDD)
 Mechanism of action, 5, 9, 14, 17, 19, 20, 22,
 47, 51, 54, 159, 165–166, 170–172,
 176, 177, 181–183, 185–189, 191,
 193, 194, 213, 215
 Mesolimbic pathway, 109, 111, 112
 Meta-analysis, 89–91, 121, 145, 169, 173,
 174, 176, 179–181, 183, 188, 191,
 192, 262
 Metabolic syndrome, 79, 92, 122, 123
 Mianserin, 169, 213, 214, 216, 218–220, 224,
 225, 250
 Mirtazapine, 6, 8, 14, 15, 19, 48, 50, 54, 56, 62,
 63, 65, 70, 165, 167, 169, 195, 213,
 214, 216–220, 224–226, 250, 270
 Mitochondrial dysfunction, 12
 Modafinil, 195
 Monoamine oxidase inhibitor (MAOI),
 19, 48–52, 54, 68–70, 165, 271
 Monotherapy, 14, 15, 39, 53, 56, 76, 81, 83,
 86–93, 98, 99, 107–124, 128, 139,
 141, 142, 144–148, 151, 152,
 159–161, 163, 169, 173, 175, 195,
 212, 215, 221, 224, 226, 250, 256,
 257, 262
 Mood stabilizers, 21, 78, 131, 138, 141,
 148–152, 162–164, 170–176, 195,
 221, 235, 261, 272
 Mortality, 48, 85, 87, 98, 99, 118, 159, 176,
 221, 225, 256, 260
 Multiple psychiatric medication,
 3–22, 258
 Multi-target, 157–196

N

N-acetylcysteine, 180
 Nefazodone, 8, 63, 65, 70, 165, 213, 216, 217,
 219, 222, 271
 Negative symptoms, 39, 91, 99, 109, 112, 113,
 118, 133, 150, 165–169, 172–180,
 182, 184, 187, 188, 190, 195,
 213–216, 220, 225

- Neuroactive, 182
 Neuroleptic, 80, 81, 128–133, 165, 167, 170, 175–178
 Neurosteroid, 180–182
 Neurotransmitters, 13, 19, 20, 40, 48, 54, 160, 168, 170, 178, 181, 183, 212, 222, 223
N-methyl-D-aspartate (NMDA), 172, 177–181, 186, 214
 Non-steroidal anti-inflammatory drug (NSAID), 53, 70, 186–187, 249, 250
 Norepinephrine transporter, 122
 NSAID. *See* Non-steroidal anti-inflammatory drug (NSAID)
- O**
 Obsessive, 17, 168, 260, 265
 Obsessive-compulsive disorder (OCD), 17, 168, 265
 Olanzapine, 8, 17, 22, 28, 29, 49, 54, 61, 62, 70, 78, 81, 82, 118, 120, 121, 144–146, 163, 173, 178, 180, 217, 218, 220, 223, 224, 268
 Omega-3 fatty acids, 192
 Open-label trial, 92, 178, 185, 215, 238, 250
 Oxcarbazepine, 62, 63, 70, 171, 172, 175, 272
 Oxidant stress, 12
- P**
 Paliperidone, 8, 28, 29, 56, 70, 120, 121, 268
 Panic disorder, 15, 22, 168, 263, 264
 PANSS. *See* Positive and negative symptom scale (PANSS)
 Parkinson' disease, 9, 10, 12–13, 16, 55, 85, 86, 173, 176
 Perphenazine, 63, 70, 173, 223, 268
 Pharmacodynamic, 6, 7, 12, 14–22, 46–57, 68, 111, 115–117, 119, 123, 139, 222–225
 Pharmacokinetics, 6, 14–22, 40, 46, 57–66, 68, 69, 98, 108, 111, 115–117, 121, 123, 139, 222–225
 Phenobarbital, 62, 63, 65, 171, 172
 Pindolol, 5, 17, 191–192, 195
 Polymorbidity, 46, 59, 61, 66, 111, 117, 121, 161, 184, 194
 Polypharmacy, 5, 46, 75, 107, 130, 138, 159, 221, 246
 Positive and negative symptom scale (PANSS), 167, 169, 173, 174, 178, 179, 184–189, 193, 217, 222
- Post traumatic stress disorder (PTSD), 15, 238
 Predictors, 76, 83–87, 169, 176, 177, 259
 Pregnenolone (PREG), 181, 182
 Prescription, 46, 51, 67, 68, 80–83, 86, 92, 94–98, 132, 138, 139, 143, 145–147, 150–152, 161, 163, 164, 176, 249, 251, 260, 263
 Prevalence, 76, 79–83, 86, 93, 95, 98, 99, 139, 150, 195, 212, 217, 234, 258, 261
 Propranolol, 62, 191, 195
 Psychosis, 7, 9, 53–54, 77, 83, 84, 92, 95, 108, 111, 122, 143, 147, 151, 158, 160, 168, 172, 174, 183, 190, 191, 212, 213, 215, 217, 221, 225, 239, 247, 257
 Psychotropics, 7, 8, 21, 46, 47, 50, 55–66, 68–71, 78, 85, 86, 97, 138, 141, 148, 149, 160, 162–164, 221, 222, 225, 238, 244, 246–249, 257–261, 263, 267–275
 PTSD. *See* Post traumatic stress disorder (PTSD)
- Q**
 QT interval, 46, 53, 56, 224
 Quetiapine, 8, 28, 29, 53, 54, 56, 63, 65, 70, 77, 81, 120, 122, 131, 146, 163, 269
- R**
 Raloxifene, 182–184
 Randomized controlled trials (RCT), 76, 91, 140, 168, 226, 250, 262
 RCT. *See* Randomized controlled trials (RCT)
 Real-world, 137–152, 163–164, 220, 259
 Remission, 14, 15, 19, 118, 259, 260
 Retinoid acid, 184, 185
 Risperidone, 8, 22, 28, 29, 56, 63, 65, 70, 77, 78, 81, 118, 120, 121, 131, 138, 144–146, 163, 166–168, 173, 178–180, 188, 214, 218–220, 223, 224, 269
 Ritanserin, 169, 214
- S**
 S-adenosyl L-methionine (SAME), 52, 194
 SANS. *See* Scale for the Assessment of Negative Symptoms (SANS)

Sarcosine, 177, 179, 180

Scale for the Assessment of Negative Symptoms (SANS), 169, 179, 190

Schizoaffective disorder, 21, 118, 140, 157–196, 213, 221, 260

Schizophrenia, 7, 27, 54, 76, 108, 127, 137, 157, 211, 239, 247

Second generation antipsychotic (SGAs), 30, 69, 81, 82, 91, 92, 98, 111, 131, 145, 160, 167, 168, 173, 178, 212, 214, 215, 217–219, 221, 225, 226

Sedatives, 8, 19, 55, 151, 164, 176, 177, 223, 272, 273

Seizure-like symptoms, 235–238

Seizures, 15, 54, 59, 120, 121, 224, 234–239

Selective serotonin reuptake inhibitor (SSRI), 6, 9, 13, 14, 16–20, 22, 49, 51–53, 55, 70, 165, 166, 169, 213, 216, 218–220, 222–225, 250, 251, 259–260, 269–271

Sensitization, 186, 233–240

Serotonin, 15, 17–20, 26, 27, 29–32, 34, 36–40, 47–55, 70, 78, 110, 111, 113, 120–123, 213, 214

 norepinephrine reuptake inhibitor (SNRI), 49, 51–53, 55, 70, 219, 220, 222, 250, 270, 272, 273

 syndrome, 48–53, 70

 transporter, 19, 20, 47

SGAs. *See* Second generation antipsychotic (SGAs)

SNRI. *See* Serotonin

Somatic symptom disorders, 243–251

Somatization, 244, 245, 247, 251

Somatoform, 244–247, 249, 250

SSRI. *See* Selective serotonin reuptake inhibitor (SSRI)

St. John's wort, 49, 52, 65, 250

Stress, 12, 15, 181–183, 193, 213, 233–240

Supplement, 27, 46, 47, 51, 52, 67, 69, 121, 161, 163, 192, 194–196, 249

T

Targretin, 185

TCA. *See* Tricyclic antidepressant (TCA)

Testosterone, 182–184

Therapeutic class, 5, 15, 268–274

Thioridazine, 49, 55, 56, 63, 70, 224, 269

Thiothixene, 269

Tolerability, 6, 9, 11, 12, 14–16, 19, 21, 89, 91, 118, 120, 144, 160, 193, 195, 214, 221–225, 238

Topiramate, 6, 62, 65, 171, 172, 175, 238, 272

Trade names, 268–275

Trazodone, 8, 17, 20, 47, 52, 54, 56, 63, 65, 165, 167–169, 213, 216, 219, 224, 271

Treatment

 cost, 85, 87, 98

 resistance/resistant, 6, 66, 76, 86, 92, 98, 99, 115, 117, 119–121, 123, 124, 174, 180, 212, 226, 237–239, 248, 251, 260, 261

Tricyclic antidepressant (TCA), 16, 47, 49, 51, 52, 55, 68, 70, 165, 216, 218, 222–225, 237, 250, 269–271

Trifluoperazine, 70, 224, 269

Trimipramine, 56, 65, 165, 226, 271

Tryptophan, 52, 186

U

USA, 55, 94, 96, 258

V

Valproate, 5, 18, 21, 22, 52, 58, 70, 151, 170–173, 175, 195, 235, 238, 272

Venlafaxine, 6, 8, 14, 15, 19, 52, 56, 63, 65, 165, 250, 272

Violence, 108

Vitamin, 58, 184, 185, 249

Z

Zinc,

Ziprasidone, 8, 28, 29, 55–57, 63, 70, 78, 118, 120, 122, 269